Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Chang

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Science Advances|June 4, 2025
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learningMulki Mehari, Gayathri Warrier, Abraham Dada, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade GliomaShawn L Hervey-Jumper, Yalan Zhang, Joanna J Phillips, et al.
Brain Pathology (Zurich, Switzerland)|October 15, 2019
Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic featuresCalixto-Hope G Lucas, Javier E Villanueva-Meyer, Nicholas Whipple, et al.
JAMA Oncology|February 7, 2020
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed GlioblastomaAnnette M Molinaro, Shawn Hervey-Jumper, Ramin A Morshed, et al.
Acta Neuropathologica Communications|August 30, 2020
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumorCalixto-Hope G Lucas, Rohit Gupta, Pamela Doo, et al.
Neuro-Oncology|December 12, 2024
Machine learning-based prognostic subgrouping of glioblastoma: A multicenter studyHamed Akbari, Spyridon Bakas, Chiharu Sako, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Science Advances|June 4, 2025
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learningMulki Mehari, Gayathri Warrier, Abraham Dada, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade GliomaShawn L Hervey-Jumper, Yalan Zhang, Joanna J Phillips, et al.
Brain Pathology (Zurich, Switzerland)|October 15, 2019
Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic featuresCalixto-Hope G Lucas, Javier E Villanueva-Meyer, Nicholas Whipple, et al.
JAMA Oncology|February 7, 2020
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed GlioblastomaAnnette M Molinaro, Shawn Hervey-Jumper, Ramin A Morshed, et al.
Acta Neuropathologica Communications|August 30, 2020
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumorCalixto-Hope G Lucas, Rohit Gupta, Pamela Doo, et al.
Neuro-Oncology|December 12, 2024
Machine learning-based prognostic subgrouping of glioblastoma: A multicenter studyHamed Akbari, Spyridon Bakas, Chiharu Sako, et al.
Pageof 12